Skip to main content
| News

The pharma centers of Basel and India are influencing each other

21.02.2020

Basel has long been one of the world’s most important locations within the pharmaceutical industry. But pharma firms are now starting to play an even bigger role in India as well. Both locations are influencing each other, as shown by the recently ended BioAsia event.

Anke Hollnagel, Director Asia at BaselArea.swiss

Large Indian pharma companies are currently focusing on generics and biosimilars in particular, while Basel-based firms such as Novartis and Roche carry out large-scale research projects, as detailed in a guest article on swissinfo.ch by Anke Hollnagel, Director Asia of the local business promotion organization BaselArea.swiss. However, there are also parallels and mutually beneficial influences between the two locations.

In this way, four startups based in Basel – namely Cellestia, Bottmedical, Artidis und Noul – presented their businesses within the framework of the BioAsia India event, which was held in Hyderabad on February 17-20, 2020. The Swiss delegation came at the initiative of Switzerland Global Enterprise (S-GE), a Swiss foreign trade promotion organization. The delegation also included representatives from BaselArea.swiss, which promoted the economic area of Basel at the event.

However, the interest is ever stronger in the other direction, as Anke Hollnagel notes in her article. In this context, Basel is becoming an attractive location for ever more Indian firms. These companies are active particularly in the areas of the Internet of Things (IoT), Artificial Intelligence (AI) and Machine Learning, and they are offering their services to Basel-based firms operating in the field of life sciences. In this way, they are driving the development of the life sciences sector towards digital healthcare and data-led personalized medicine. According to Anke Hollnagel, this influence will increase yet further over the coming years as Indian firms develop. The major Indian pharma group Dr. Reddy’s has already established a strong presence in Basel.

BaselArea.swiss recognized this development a long time ago and has placed a stronger focus on the Indian market in the past year. This focus will be sustained throughout 2020 as well.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

KetoSwiss secures capital increase of 4 million dollars

KetoSwiss has banked a total of 4 million US dollars from investors. The Basel-based startup develops products to alleviate neurological...

Read More
Basel Area Business & Innovation, Invest, Life Sciences / biotech

Escientia Switzerland becomes Primopus

The Indian company Deccan Fine Chemicals is acquiring Escientia Switzerland and renaming it as Primopus AG. The new owner announces...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Novartis investing 100 million Swiss francs in new biologics center

The pharmaceutical company Novartis is investing a sum of 100 million Swiss francs in a new competence center for biologics...

Read More
1 2 3 35

Do you have a question? We'd like to hear from you.